Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Clinical implementation of comprehensive strategies to characterize cancer genomes: opportunities and challenges.

MacConaill LE, Van Hummelen P, Meyerson M, Hahn WC.

Cancer Discov. 2011 Sep;1(4):297-311. doi: 10.1158/2159-8290.CD-11-0110. Review.

2.

A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.

Dietel M, Jöhrens K, Laffert MV, Hummel M, Bläker H, Pfitzner BM, Lehmann A, Denkert C, Darb-Esfahani S, Lenze D, Heppner FL, Koch A, Sers C, Klauschen F, Anagnostopoulos I.

Cancer Gene Ther. 2015 Sep;22(9):417-30. doi: 10.1038/cgt.2015.39. Review.

PMID:
26358176
3.
4.

Prioritizing targets for precision cancer medicine.

Andre F, Mardis E, Salm M, Soria JC, Siu LL, Swanton C.

Ann Oncol. 2014 Dec;25(12):2295-303. doi: 10.1093/annonc/mdu478. Review.

PMID:
25344359
5.

Exploring the genomes of cancer cells: progress and promise.

Stratton MR.

Science. 2011 Mar 25;331(6024):1553-8. doi: 10.1126/science.1204040. Review.

PMID:
21436442
6.

Impact of tumor sequencing on the use of anticancer drugs.

Thomas F, Desmedt C, Aftimos P, Awada A.

Curr Opin Oncol. 2014 May;26(3):347-56. doi: 10.1097/CCO.0000000000000078. Review.

PMID:
24709974
7.

Targeting FGFR Signaling in Cancer.

Touat M, Ileana E, Postel-Vinay S, André F, Soria JC.

Clin Cancer Res. 2015 Jun 15;21(12):2684-94. doi: 10.1158/1078-0432.CCR-14-2329. Review.

8.

Exploiting genetic complexity in cancer to improve therapeutic strategies.

Garnett MJ, McDermott U.

Drug Discov Today. 2012 Mar;17(5-6):188-93. doi: 10.1016/j.drudis.2012.01.025.

9.

Translating cancer genomes and transcriptomes for precision oncology.

Roychowdhury S, Chinnaiyan AM.

CA Cancer J Clin. 2016 Jan-Feb;66(1):75-88. doi: 10.3322/caac.21329. Review.

10.

Implementing personalized cancer genomics in clinical trials.

Simon R, Roychowdhury S.

Nat Rev Drug Discov. 2013 May;12(5):358-69. doi: 10.1038/nrd3979. Review.

PMID:
23629504
11.

Designing transformative clinical trials in the cancer genome era.

Sleijfer S, Bogaerts J, Siu LL.

J Clin Oncol. 2013 May 20;31(15):1834-41. doi: 10.1200/JCO.2012.45.3639. Review.

PMID:
23589555
12.

National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network.

Abrams J, Conley B, Mooney M, Zwiebel J, Chen A, Welch JJ, Takebe N, Malik S, McShane L, Korn E, Williams M, Staudt L, Doroshow J.

Am Soc Clin Oncol Educ Book. 2014:71-6. doi: 10.14694/EdBook_AM.2014.34.71. Review.

13.

Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.

Frampton GM, Ali SM, Rosenzweig M, Chmielecki J, Lu X, Bauer TM, Akimov M, Bufill JA, Lee C, Jentz D, Hoover R, Ou SH, Salgia R, Brennan T, Chalmers ZR, Jaeger S, Huang A, Elvin JA, Erlich R, Fichtenholtz A, Gowen KA, Greenbowe J, Johnson A, Khaira D, McMahon C, Sanford EM, Roels S, White J, Greshock J, Schlegel R, Lipson D, Yelensky R, Morosini D, Ross JS, Collisson E, Peters M, Stephens PJ, Miller VA.

Cancer Discov. 2015 Aug;5(8):850-9. doi: 10.1158/2159-8290.CD-15-0285.

14.

Improving the evaluation of new cancer treatments: challenges and opportunities.

Rothenberg ML, Carbone DP, Johnson DH.

Nat Rev Cancer. 2003 Apr;3(4):303-9. Review.

PMID:
12671669
15.

Personalized cancer therapy with selective kinase inhibitors: an emerging paradigm in medical oncology.

McDermott U, Settleman J.

J Clin Oncol. 2009 Nov 20;27(33):5650-9. doi: 10.1200/JCO.2009.22.9054. Review.

PMID:
19858389
16.

Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology.

Vogelzang NJ, Benowitz SI, Adams S, Aghajanian C, Chang SM, Dreyer ZE, Janne PA, Ko AH, Masters GA, Odenike O, Patel JD, Roth BJ, Samlowski WE, Seidman AD, Tap WD, Temel JS, Von Roenn JH, Kris MG.

J Clin Oncol. 2012 Jan 1;30(1):88-109. doi: 10.1200/JCO.2011.40.1919.

PMID:
22147736
17.

Cancer pharmacogenomics: strategies and challenges.

Wheeler HE, Maitland ML, Dolan ME, Cox NJ, Ratain MJ.

Nat Rev Genet. 2013 Jan;14(1):23-34. doi: 10.1038/nrg3352. Review.

18.

Cancer heterogeneity: implications for targeted therapeutics.

Fisher R, Pusztai L, Swanton C.

Br J Cancer. 2013 Feb 19;108(3):479-85. doi: 10.1038/bjc.2012.581. Review.

19.

Towards systematic functional characterization of cancer genomes.

Boehm JS, Hahn WC.

Nat Rev Genet. 2011 Jun 17;12(7):487-98. doi: 10.1038/nrg3013. Review.

PMID:
21681210
20.

Exploring the cancer genome in the era of next-generation sequencing.

Dong H, Wang S.

Front Med. 2012 Mar;6(1):48-55. doi: 10.1007/s11684-012-0182-x. Review.

PMID:
22460448
Items per page

Supplemental Content

Support Center